Pentoxifylline Lifts the Burden of PreeclampsiaArsalan Azimi*
Histomorphometry and Stereology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran
- *Corresponding Author:
- Arsalan Azimi
Histomorphometry and Stereology Research Centre
Shiraz University of Medical Sciences, Shiraz, Iran
Tel: +98 (0) 9379876373
E-mail: [email protected]
Received: November 30, 2015 Accepted: January 04, 2016 Published: January 09, 2016
Citation: Azimi A (2016) Pentoxifylline Lifts the Burden of Preeclampsia. J Blood Disord Transfus 7:332. doi:10.4172/2155-9864.1000332
Copyright: © 2016 Azimi A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.
Worldwide, Preeclampsia is the leading cause of maternal morbidity and perinatal mortality and it initiates as inappropriate immune response to trophoblastic invasion impairs placentation and placental circulation followed by generation of superoxide anions as well as anti-angiogenic factors and this series of events result in impairment of maternal/placental endothelial function, maternal hypertension, kidney injury, proteinuria and thromboembolic events. Renal loss of anti-coagulant proteins and subsequent hyper-coagulable state along with endothelial dysfunction accelerates progression of the disease toward eclampsia. Pentoxifylline, could hypothetically modify pathophysiological mechanisms of preeclampsia including impaired immune response, placentation, endothelial function and coagulation, so it could explore new horizons in treatment of preeclampsia.